Conditions: Recurrent Prostate Carcinoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys\[Ahx\]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying prostate cancer that may have returned after a period of improvement (biochemical recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer receptor, which can then be imaged by the PET/CT or PET/MRI scanner.

Detailed description:
PRIMARY OBJECTIVES:

Evaluate the feasibility and biodistribution of 68Ga-PSMA.

OUTLINE:

Patients are injected with 5 mCi of Ga68 PSMA intravenously (IV) and then undergo PET/CT or PET/MRI approximately 45 to 60 minutes later.

After completion of study, patients are followed up at 24 hours and 1 week.

Arms:
arm 1: Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.

Interventions: intervention 1: Computed Tomography intervention 2: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx) intervention 3: Magnetic Resonance Imaging intervention 4: Positron Emission Tomography
Intervention descriptions: intervention 1: Part of PET/CT scan intervention 2: Intravenously-administered (IV) radioisotope intervention 3: Part of PET/MRI scan intervention 4: Part of PET/CT and/or PET/MRI scans

Protocol document: